Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Stavudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ALB | P02768 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 10/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | TK2 | O00142 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stavudine SCHEMBL8185422 | 1.00 | LMNA (0.60) | LMNAALBALDH1A1POLBADRA1A | |
| Didanosine SCHEMBL3639266 | 0.90 | LMNA (0.57) | LMNAALBALDH1A1POLBADRA1A | |
| Stavudine SCHEMBL28086387 | 0.86 | ALB (0.64) | LMNAALBALDH1A1POLBADRA1A | |
| Stavudine SCHEMBL4773402 | 0.86 | ALB (0.64) | LMNAALBALDH1A1POLBADRA1A | |
| Didanosine SCHEMBL23925471 | 0.84 | ALB (0.50) | LMNAALBALDH1A1POLBADRA1A | |
| Lamivudine SCHEMBL22364335 | 0.83 | ALB (0.65) | LMNAALBBLMCACNA1FMAPT | |
| Doxecitine SCHEMBL9803658 | 0.83 | LMNA (0.50) | LMNAALBBLMTK2 | |
| Cytidine SCHEMBL574775 | 0.81 | LMNA (0.62) | LMNATK2 | |
| Zalcitabine SCHEMBL8094882 | 0.80 | LMNA (0.62) | LMNAALBALDH1A1POLBCACNA1F | |
| Zalcitabine SCHEMBL598496 | 0.80 | LMNA (0.62) | LMNAALBALDH1A1POLBCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10639276-B2 | Liposomes with ginsenoside as membrane material and preparations and use thereof | SHANGHAI GINPOSOME PHARMATECH CO., LTD. (CN) | 2020-05-05 | — | — | US | claimed |
| EP-3337456-A1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | Shanghai Ginposome Pharmatech Co., Ltd. (CN) | 2018-06-27 | — | — | EP | claimed |
| US-20170172920-A1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | Xiamen Ginposome Pharmaceutical Co., Ltd. (CN) | 2017-06-22 | — | — | US | claimed |
| WO-2017028811-A1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO., LTD. (CN) | 2017-02-23 | — | — | WO | claimed |
| US-20230101559-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20220017511-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2022-01-20 | — | — | US | disclosed |
| US-20210253551-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3825313-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210130346-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3800182-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210047304-A1 | Bromodomain Inhibitors | ABBVIE INC. | 2021-02-18 | — | — | US | disclosed |
| US-20140275079-A1 | PYRROLE AMIDE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
| WO-2013185284-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | ABBOTT LABORATORIES (US) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013158952-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013155695-A1 | ISOINDOLONE DERIVATIVES | ABBOTT LABORATORIES (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281450-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. | 2013-10-24 | — | — | US | disclosed |
| WO-2013097052-A1 | BROMODOMAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2003026577-A2 | P-AMIDOBENZYLETHERS IN DRUG DELIVERY AGENTS | SEATTLE GENETICS, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047304-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | LMNA 1189/4885ALB 4835/4885ALDH1A1 2378/4885 |
| US-20210253551-A1 | Bromodomain Inhibitors | BRD4, BRD3, BRD1 | LMNA 2472/4885ALB 4853/4885ALDH1A1 3680/4885 |
| US-20220017511-A1 | Bromodomain Inhibitors | BRD4, BRD3, BRD1 | LMNA 2379/4885ALB 4849/4885ALDH1A1 3060/4885 |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | LMNA 2930/4885ALB 4785/4885ALDH1A1 2163/4885 |
| US-10639276-B2 | Liposomes with ginsenoside as membrane material and preparations and use thereof | SGMS1, LIPA, SGMS2 | LMNA 320/4885ALB 4249/4885ALDH1A1 4412/4885 |
| US-20210130346-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | LMNA 1652/4885ALB 4740/4885ALDH1A1 1910/4885 |
| US-20140275079-A1 | PYRROLE AMIDE INHIBITORS | HDAC10, ARG1, CDK20 | LMNA 4623/4885ALB 3070/4885ALDH1A1 844/4885 |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | LMNA 2455/4885ALB 4831/4885ALDH1A1 1531/4885 |
| US-20130281450-A1 | ISOINDOLONE DERIVATIVES | CYP11B1, HSD17B7, CYP4A11 | LMNA 3610/4885ALB 4779/4885ALDH1A1 327/4885 |
| US-20170172920-A1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SGMS1, LIPA, SGMS2 | LMNA 320/4885ALB 4249/4885ALDH1A1 4412/4885 |
| US-20230101559-A1 | Bromodomain Inhibitors | BRD4, BRD3, BRD1 | LMNA 2472/4885ALB 4853/4885ALDH1A1 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.